Kornimate/medical-research-clean huggingface dataset:
comparing single photon emission computed tomography (spect) and liver biopsy to evaluate the liver in patients with hiv and hepatitis c virus

Conditions: HIV Infections; Hepatitis C

Summary: the purpose of this study is to find if the single photon emission computed tomography (spect) scan is as effective as a liver biopsy (using a special needle to remove tissue from the liver) in examining liver damage in patients with hiv and hepatitis c virus (hcv). a standard way to examine the liver for disease has been to perform a liver biopsy. the spect scan, which takes a picture of the liver, has been found to be effective in determining liver damage but studies need to be done in patients with hepatitis. this study will compare the effectiveness of the liver biopsy and spect scan in determining liver disease in patients with hiv and hcv. the spect scan might be a good replacement for the liver biopsy if it is found to be as good as or better than liver biopsies.

assessment with a liver biopsy is currently the standard of practice to determine the status of liver involvement in patients with hcv. a direct comparison between spect results and liver pathology has been examined in patients with liver disease other than infectious hepatitis. spect has been found to be more accurate than standard liver-spleen scans in assessing liver pathology. while current data suggest that liver pathology may correlate with spect, which specific spect parameters are predictive of certain hepatic pathology is unknown. the pilot study will compare spect parameters with the results of liver biopsies to determine the limitations of spect. all screened patients are registered into step 1, in which they receive a radioactive tracer injection and spect scan. specific spect parameters will be measured to determine a grading scale corresponding to that used in liver biopsy results. some patients undergoing a second liver biopsy in a5071 are enrolled into step 2, with permission from protocol co-chairs, in which a pregnancy test and second spect scan are performed. patients are reimbursed for completing each spect scan. spect scans or copies are reviewed to establish which parameters correspond to category e of the knodell stage based on severity of fibrosis.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are enrolled in, or will soon enroll in, a5071. patients may be eligible for the study if they are screening for a5071 and have a liver biopsy and spect scan but do not enter a5071. patients who have stopped taking a5071 study drugs may also be eligible. * have had a liver biopsy, or will soon have a liver biopsy. * have a spect scan either before the liver biopsy or 2 weeks to 8 weeks after a liver biopsy. * intend to have the spect scan within 7 days of study entry. exclusion criteria patients will not be eligible for this study if they: * are allergic to chemicals in the radioactive tracer used for the spect scan. * are pregnant or breast-feeding.

Keywords: liver hepatitis c biopsy tomography, emission-computed, single-photon
upper gi symptoms in patients receiving acetylsalicylic acid/nsaids - nsaids wave 2

Conditions: Upper-GI Symptoms

Summary: the current epidemiological study will be undertaken in gp's and specialized private doctors. in total, 85 general practitioners, orthopedics, rheumatologists and cardiologist will take part in the study. data will be collected for 850 patients who visit their physician for medical conditions that require the use of acetylsalicylic acid and/or nsaids. the first 10 consecutive patients who visit their gp/orthopedic/rheumatologist/cardiologists and are currently receiving acetylsalicylic acid and/or nsaids will be included in the study.


Eligibility criteria:
inclusion criteria: * acetylsalicylic acid/nsaids intake for at least 5 days of a week during the past month before the patient's visit to the clinician exclusion criteria: * patients who are not willing to sign of the informed consent form

Keywords: upper gi symptoms gerd nsaids
tapse/pasp anesthesia

Conditions: Hypotension

Summary: tapse, one of the methods for evaluating right ventricular systolic function; it is a bar parameter that can easily measure apex-basal shortening and provides specific information about global rv function. tapse/pasp can be calculated as load-independent parameters to evaluate rv function. because rv function is sensitive to change in afterload, known as the rv-pulmonary circulation (pc) connection. this study aims to identify patients who are candidates for hypotensive events due to general anesthesia in a hemodynamically stable population.

tapse, one of the methods for evaluating right ventricular systolic function; it is a bar parameter that can easily measure apex-basal shortening and provides specific information about global rv function. tapse/pasp can be calculated as load-independent parameters to evaluate rv function. because rv function is sensitive to change in afterload, known as the rv-pulmonary circulation (pc) connection. this study aims to identify patients who are candidates for hypotensive events due to general anesthesia in a hemodynamically stable population. patients will be measured by transthoracic echocardiography in the preoperative period, 15-30 minutes before induction. basal hemodynamic parameters and non-invasive and/or hemodynamic values will be recorded every two minutes after induction until surgical incision.patients with a 30% decrease in sbp from the baseline and a decrease in map below 65 mmhg in the first 10 minutes after anesthesia induction will be considered to have hypotension. patients will be divided into 2 groups: 'with' and 'without' hypotension.

Eligibility criteria:
inclusion criteria: 1. written informed consent; 2. 18-75 years old 3. asa physical status 1-3; 4. patients planned for pulmonary resection surgery exclusion criteria: 1. the patient is pregnant 2. after cardiac surgery 3. severe pulmonary hypertension 4. severe valve disease 5. hypertrophic or dilated cardiomyopathy 6. presence of acute myocardial infarction 7. patients with severe visual or hearing impairment/disability 8. asa physical status iv or v 9. ischemic heart disease, conduction disorder. 10. history of long-term use of certain medications (β-blockers, angiotensin converting enzyme inhibitors, analgesics, sedatives or tricyclic antidepressants)

Keywords: tapse pasp hypotensi̇on pulmoner resecti̇on
body composition changes during stem cell transplantation: the case of lymphoma patients

Conditions: Hematopoietic Stem Cell Transplantation; Malnutrition; Metabolic Syndrome

Summary: skeletal muscle index (smi) and visceral adipose ratio (var) assess body composition changes and disclose malnutrition risk effectively. the aims of the study are to assess prevalence of malnutrition in patients planned for sct, to characterize changes in body composition (smi, total adipose tissue and var) that occur in the peri transplantation phase, and to identify waist circumference (wc) cut off points associated with the metabolic syndrome (metsyn) in patients with b and t cell lymphoma.

this study is a retrospective cohort study of patients having b and t cell lymphoma, who underwent sct in the bone marrow transplantation (bmt) unit at aubmc. consecutive patients having b and t lymphoma who underwent sct at aubmc will be identified by the research team and will be included as per the below inclusion and exclusion criteria. starting from june 2016, patients who meet the inclusion criteria will be included in the study up until june 2006. the radiologist will access the aubmc pacs system to review pet/ct scans of the identified patients. smi, visceral, subcutaneous and intramuscular adipose tissues will be established by assessing at the level of l3.

Eligibility criteria:
inclusion criteria: * age\>16 years * patients having b and t cell lymphoma who have undergone sct at aubmc exclusion criteria: * patients with a missing pre-sct pet/ ct scan * patients with 2 missing post sct pet / ct scan

Keywords: skeletal muscle index visceral adipose tissue metabolic syndrome
gh21 capsules for advanced solid tumors: a study on safety and early results

Conditions: Advanced Solid Tumor; Non-Small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; Head and Neck Neoplasm

Summary: evaluate the safety and tolerability of gh21 in patients with advanced solid tumors. estimate the maximum tolerated dose (mtd) in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. male or female subjects greater than or equal to 18 years old； 2. written informed consent obtained prior to any study-related procedure being performed; 3. subjects with life expectancy ≥3 months; 4. eastern cooperative oncology group performance score 0 - 2; 5. subjects must have histologically or cytologically confirmed advanced or metastatic solid tumor; 6. at least one measurable lesion based on recist version 1.1 . exclusion criteria: 1. history of other malignancies within 3 years before screening,unless radical non-melanoma skin cancer or basal cell carcinoma of the skin or carcinoma in the situ of the cervix; 2. have central nervous system metastases; 3. prior treatment with shp2 inhibitor; 4. have major surgery within 28 days prior to the first dose of gh21; 5. left ventricular ejection fraction (lvef) \<50 %; 6. females who are pregnant or breastfeeding ; 7. active hepatitis b virus (hbv) or hepatitis c virus (hcv) infection; 8. conditions that the investigator considers inappropriate for participation in this clinical trial.
effect of kinesio taping on muscle strength in quadriceps femoris

Conditions: Anterior Knee Pain; Muscle Weakness; Knee Symptoms

Summary: the purpose of this project is to investigate the effect of kinesio tape on muscle strength of the quadriceps femoris in people with knee pain or symptoms and decreased muscle strength in the quadriceps femoris - a randomized controlled trial.

the aim of the study is to investigate the effect of recoil tape with 0-30% tension, by using one application of kinesio tape over the muscle fibers of the quadriceps femoris from its origin to its insertion. the participants will be divided into intervention group (taping) and control group (no intervention). muscle strength test will be performed before and immediately after taping (20-30 minutes) for both groups using hand-held dynamometer measurements (microfet 3). work is based on the following hypothesis: "kinesio taping using recoil taping provides increased isometric muscle strength in quadriceps femoris immediately after application".

Eligibility criteria:
inclusion criteria: * shoulder problems * low muscle strength in quadriceps femoris * positive manual recoil-test for the quadriceps femoris exclusion criteria: * knee surgery \<3 month * pathology in the knee related to tumors, fractures, neurology, rupture of tendons
efficacy testing of collagen peptide drink

Conditions: Skin Condition

Summary: to assess collagen peptide drink on skin condition improvement


Eligibility criteria:
inclusion criteria: * healthy adults aged above 20 years old exclusion criteria: * subject who is not willing to participate in this study. * patients with diseases of the skin, liver, kidney. * subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder. * female who is pregnant or nursing or planning to become pregnant during the course of the study. * received facial laser therapy, chemical peeling or uv overexposure in the past 4 weeks. * constant drug use * participated cosmetic product human study in the past 3 months.
magnetic resonance whole body diffusion-weighted imaging in finding bone or lymph node metastasis in participants with high-risk prostate cancer

Conditions: Prostate Carcinoma

Summary: this trial studies how well magnetic resonance whole body diffusion-weighted imaging works in finding cancer that has spread to the bone or lymph nodes (metastasis) in participants with high-risk prostate cancer. diagnostic procedures, such as magnetic resonance whole body diffusion-weighted imaging (a method to show how water moves in a certain area) may help find bone or lymph nodes metastasis.

primary objectives: i. to compare accuracies of whole body magnetic resonance imaging (mri) versus bone scan plus computed tomography (ct) scan in detecting bone or lymph node metastasis in high risk prostate cancer patients. outline: participants undergo standard of care bone scan, ct of the abdomen and pelvis, and pelvic mri. participants also undergo magnetic resonance whole body (wb)-diffusion-weighted imaging (dwi) over 20-30 minutes.

Eligibility criteria:
inclusion criteria: * prostate carcinoma patients at high risk for metastasis with prostate-specific antigen (psa) more than 20 ng/ml and/or gleason score = 8/ \> 8. * ability to understand and sign informed consent. exclusion criteria: * patient is at low risk for metastasis with gleason score at diagnosis \< 8. * currently receiving or history of systemic therapy with testosterone suppressing medication (i.e., lupron, degarelix, abiraterone, enzalutamide) or local radiation therapy. * contraindication to magnetic resonance imaging (mri).
comparison of anterior chamber paracentesis and conventional mannitol infusion in patients with primary acute angle-closure glaucoma

Conditions: Glaucoma; Acute Primary Angle-closure Glaucoma

Summary: the investigators wanted to reported the results of immediate anterior chamber paracentesis (acp), compared to mannitol infusion, in patients with acute primary angle-closure glaucoma (pacg). in this study, the investigators first divided patients into three sub-groups according to their initial intraocular pressure (iop) for analyzing the differences of iop control, severity of corneal edema, waiting time for laser peripheral iridotomy (lpi), and visual outcome between acp and mannitol infusion.

the investigators demonstrated that acp could be first considered in patients with initial iop between 45 to 60 mmhg because it provided better visual outcome than mannitol infusion through the rapid stabilization of the anterior segment, which was achieved by rapid iop control, better corneal edema regression, shortening waiting time for lpi. however, acp should be considered in patients with the initial iop of 60mmhg and higher only when mannitol was contraindicated.

Eligibility criteria:
inclusion criteria: * first attack of acute pacg; * initial presenting iop was higher than 45 mmhg; * diagnosis confirmed by gonioscopic examination; * patients within 48 hours of symptom onset. exclusion criteria: * been incompletely followed up within 2 weeks; * been using anti-glaucomatous medication before acp or mannitol infusion; * previous intraocular surgeries on the same eye; * contraindication for mannitol; * history of other vision-threatening ocular diseases.

Keywords: glaucoma anterior chamber paracentesis conventional mannitol infusion
efficacy and safety of shr8028 eye drops for the treatment of dry eye disease

Conditions: Dry Eye Disease

Summary: the study is being conducted to assess the efficacy, safety and tolerability of shr8028 eye drops in comparison to the vehicle for the treatment of dry eye disease.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old; 2. provide written informed consent form; 3. have a subject reported history of dry eye disease in both eyes for at least 180 days before the screening visit (visit 0); 4. be currently (within 30 days before visit 0) using over-the-counter (otc) eye drops, lubricating gels or tear neurostimulator device (such as true teartm), and/or artificial tears for dry eye symptoms; 5. have at least one eye meets criteria of moderate to severe dry eye both at visit 0\&1 6. be able and willing to follow instructions and participate in all study assessments and visits. exclusion criteria: 1. have any clinically significant slit-lamp findings at visit 0 that require treatment with prescription drugs and/or in the opinion of the investigator may interfere with study parameters, such as trauma, stevens-johnson syndrome, or advanced epithelial basement membrane disease; 2. have dry eye disease secondary to scar formation, such as radiation, alkali burn, cicatricial pemphigus, and destruction of conjunctival goblet cells (i.e., destruction of conjunctival goblet cells caused by vitamin a deficiency); 3. have active ocular allergy or ocular allergy that may occur during the study; 4. be diagnosed with an ongoing ocular or systemic infection (bacterial, viral, or fungal), including fever, or be undergoing treatment with antibiotics at visit 0 and visit 1; 5. be a woman who is pregnant, breastfeeding, or planning pregnancy; 6. have an uncontrolled systemic disease; 7. have allergies to investigational medicinal product (imp) or its components: cyclosporin a or semi-fluorinated alkanes (sfa); 8. be currently participating in other drug or device trials, or have used other investigational drugs or devices within 60 days before visit 0; 9. have a condition which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere with the subject's participation in the study significantly; 10. have received or removed lacrimal duct embolism within 90 days before visit 0, or plan to receive or remove lacrimal duct embolism during the study.
v221 concomitant use study with pneumococcal conjugate vaccine (v221-019)

Conditions: Measles; Mumps; Rubella; Varicella

Summary: the study is being conducted to demonstrate that v221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes of s. pneumoniae.


Eligibility criteria:
inclusion criteria: * in good health * 12 to 15 months of age * negative clinical history to measles, mumps, rubella, varicella and/or zoster * received only the 3-dose primary series of a pneumococcal conjugate vaccine with at least 2 months prior to the receipt of any of the study vaccines * signed consent exclusion criteria: * previous administration of any measles, mumps, rubella, or varicella vaccine either alone or in any combination * any condition resulting in depressed immunity * any allergy to any vaccine component as stated in the package circulars * exposure to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the study vaccination * history of seizure disorder * receipt of an inactivated vaccine within 14 days prior to enrollment or live vaccine within 30 days * recent febrile illness
cook venous valve system for treatment of chronic venous insufficiency

Conditions: Venous Insufficiency of Leg

Summary: the purpose of this study is to learn about the safety, efficacy and utility of a medical device called the cook® venous valve system. this device, percutaneously placed in the leg, is meant to help the blood flow correctly through the veins in the leg.


Eligibility criteria:
limited inclusion criteria: * documented symptomatic deep venous reflux in one limb * deep venous reflux in the region of interest limited exclusion criteria: general: * age \< 18 years * bmi ≥ 40 * cultural objections to porcine materials * unwillingness or inability to comply with the follow-up * unwillingness to provide study data for duration of study * simultaneous participation in another device or drug study * inability or refusal to give informed consent medical: * pregnant, or planning to become pregnant * diagnosis of terminal illness with life expectancy less than 12 months * complete symptom resolution with compliant compression therapy for three months * untreated superficial venous disease * medical interventions including any of the following: planned procedure of any leg, vascular intervention or major surgery within the last three months, implanted inferior vena cava filter * medical history of any of the following: anticoagulation treatment for pulmonary embolism (within the last six months or ongoing), insulin dependent diabetes, chronic obstructive pulmonary disease, renal dysfunction requiring dialysis, leg amputation, bleeding diathesis, untreated or unresolved systemic infection or local infection, active malignancy except non-melanoma skin cancer, other acute or chronic medical condition that may cause noncompliance with the protocol or confound the study results, documented history of significant untreated stenosis within the arterial system * positive coronavirus (covid-19) test six days prior to implant procedure anatomical: * inability to clearly visualize target implantation site * tortuous target implantation site * inadequate inflow and/or outflow to the target region procedural: * inability to gain access to the access site vein * untreated focal or diffuse stenosis
intravascular ultrasound versus angiography guided drug-coated balloon

Conditions: Coronary Artery Disease

Summary: drug-coated balloon (dcb) is an alternative choice for denovo lesions in coronary artery disease patients with high bleeding risk. intravascular ultrasound (ivus) can provide more details of coronary anatomy and stent implantation, overcoming a number of limitations of coronary angiography. however, the benefit of ivus-guided dcb treatment has not been investigated. this study is designed to compare ivus-guided and angiography-guided dcb treatment for coronary denovo lesions in patients with high bleeding risk.

this is a prospective, multicenter, randomized controlled trial that aims to enroll 260 patients with high bleeding risk. all patients with coronary denovo lesions suitable for dcb treatment will undergo 1:1 randomization to either ivus guidance or angiography guidance using the central randomization system. all subjects will be screened according to the predefined inclusion and exclusion criteria per protocol. data and images will be collected during the index procedure, and at the predefined 7-month coronary angiography follow-up visit.

Eligibility criteria:
inclusion criteria: 1. de novo lesions, suitable for dcb treatment. 2. patients with high bleeding risk. exclusion criteria: 1. target lesion length \> 15mm. 2. severe calcified lesions. 3. left main disease. 4. ostial lesions. 5. three-vessel disease. 6. acute myocardial infarction within 48 hours. 7. target vessel received stent implantation. 8. hemodynamic instability.